Novartis strikes about $7.8 billion mRNA deal with China's AbogenOct 2, 2026Novartis has entered into a $7.8 billion licensing and option agreement with Chinese biotech firm Abogen to advance RNA-based therapies.Novartis strikes about $7.8 billion mRNA deal with China's AbogenreutersTopic tracking2026-03-24March 24 Business Watch: Helium Capacity Taken Out in Qatar; Novartis to Pay $2 Billion for Small Molecule2026-05-05Novartis to cut 220 jobs as it closes German site2026-07-20Novartis Backs Full-Year Forecast After Profit Beat Driven by One-Offs2026-09-02Novartis Could Cut About 130 Jobs in Basel Site Relocation2026-09-07Novartis falls as failed cholesterol drug study raises stakes for pipeline2026-09-07European Shares Dip as Oil Prices Rise; Novartis Slips2026-09-08European Shares Dip as Higher Crude Revives Inflation Worries; Novartis Drags2026-10-02Novartis strikes about $7.8 billion mRNA deal with China's Abogen2026-11-18Novartis targets 5% annual sales growth through 20312026-11-19Novartis trims medium-term growth target, shares fall